Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Clinical trial NCT06834373 · RECRUITING

Trial details

NCT number: NCT06834373
Sponsor: Mayo Clinic
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Large B-Cell Lymphoma With IRF4 Rearrangement Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma Recurrent ALK-Positive Large B-Cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Recurrent Grade 3b Follicular Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified Recurrent Intravascular Large B-Cell Lymphoma

Start date: 2025-04-02
Primary completion: 2027-03-03
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.